DexCom Research Development from 2010 to 2026

DXCM Stock  USD 73.16  0.07  0.1%   
DexCom Research Development yearly trend continues to be very stable with very little volatility. Research Development is likely to grow to about 629.1 M this year. During the period from 2010 to 2026, DexCom Research Development quarterly data regression pattern had sample variance of 53469.3 T and median of  273,500,000. View All Fundamentals
 
Research Development  
First Reported
2003-12-31
Previous Quarter
157.5 M
Current Value
148.2 M
Quarterly Volatility
59.5 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check DexCom financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DexCom's main balance sheet or income statement drivers, such as Interest Expense of 12.5 M, Other Operating Expenses of 3.9 B or Operating Income of 957.4 M, as well as many indicators such as Price To Sales Ratio of 5.28, Dividend Yield of 0.0 or PTB Ratio of 9.99. DexCom financial statements analysis is a perfect complement when working with DexCom Valuation or Volatility modules.
  
Build AI portfolio with DexCom Stock
Check out the analysis of DexCom Correlation against competitors.
Evaluating DexCom's Research Development across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into DexCom Inc's fundamental strength.

Latest DexCom's Research Development Growth Pattern

Below is the plot of the Research Development of DexCom Inc over the last few years. It is DexCom's Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in DexCom's overall financial position and show how it may be relating to other accounts over time.
Research Development10 Years Trend
Slightly volatile
   Research Development   
       Timeline  

DexCom Research Development Regression Statistics

Arithmetic Mean299,523,765
Geometric Mean166,000,677
Coefficient Of Variation77.20
Mean Deviation206,572,339
Median273,500,000
Standard Deviation231,234,259
Sample Variance53469.3T
Range626.2M
R-Value0.96
Mean Square Error4532.4T
R-Squared0.92
Slope43,934,056
Total Sum of Squares855508.5T

DexCom Research Development History

2026629.1 M
2025599.1 M
2024552.4 M
2023505.8 M
2022484.2 M
2021604.2 M
2020359.9 M

About DexCom Financial Statements

DexCom investors utilize fundamental indicators, such as Research Development, to predict how DexCom Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Research Development599.1 M629.1 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether DexCom Inc is a strong investment it is important to analyze DexCom's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DexCom's future performance. For an informed investment choice regarding DexCom Stock, refer to the following important reports:
Check out the analysis of DexCom Correlation against competitors.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Will Health Care Equipment & Supplies sector continue expanding? Could DexCom diversify its offerings? Factors like these will boost the valuation of DexCom. Projected growth potential of DexCom fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every DexCom data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth
0.78
Earnings Share
2.09
Revenue Per Share
11.948
Quarterly Revenue Growth
0.131
Return On Assets
0.0889
Understanding DexCom Inc requires distinguishing between market price and book value, where the latter reflects DexCom's accounting equity. The concept of intrinsic value - what DexCom's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push DexCom's price substantially above or below its fundamental value.
It's important to distinguish between DexCom's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DexCom should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, DexCom's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.